Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline.
about
Obesity and cancerIrinotecan, a key chemotherapeutic drug for metastatic colorectal cancerObesity and cancer: mechanistic insights from transdisciplinary studiesWhy does obesity promote cancer? Epidemiology, biology, and open questionsDiabetes and cancer: two diseases with obesity as a common risk factorBody mass index and survival in women with breast cancer-systematic literature review and meta-analysis of 82 follow-up studiesBody surface area formulae: an alarming ambiguityA Review of the Toxicologic Implications of ObesityAssociation of body composition with outcome of docetaxel chemotherapy in metastatic prostate cancer: a retrospective reviewBody mass index and colorectal cancer prognosis: a systematic review and meta-analysis.Higher rate of severe toxicities in obese patients receiving dose-dense (dd) chemotherapy according to unadjusted body surface area: results of the prospectively randomized GAIN study.Obesity and cancer pathogenesis.Prognostic factors in early breast cancer associated with body mass index, physical functioning, physical activity, and comorbidity: data from a nationwide Danish cohort.Reply to the letter to the editor 'Higher rate of severe toxicities in obese patients receiving dose-dense (dd) chemotherapy according to unadjusted body surface area: results of the prospectively randomized GAIN study' by Daly et al.Phase I/II study of albumin-bound nab-paclitaxel plus gemcitabine administered to Chinese patients with advanced pancreatic cancer.Role of the lean body mass and of pharmacogenetic variants on the pharmacokinetics and pharmacodynamics of sunitinib in cancer patients.Myelosuppression by chemotherapy in obese patients with gynecological cancers.Association of 15-hydroxyprostaglandin dehydrogenate and poor prognosis of obese breast cancer patients.Effect of body mass in children with hematologic malignancies undergoing allogeneic bone marrow transplantation.Body mass index and weight change in relation to triple-negative breast cancer survival.The role of adipose tissue and obesity in causing treatment resistance of acute lymphoblastic leukemia.Influence of body mass index on survival in indolent and mantle cell lymphomas: analysis of the StiL NHL1 trialPharmacokinetics of Antimicrobials in Obese Children.Not All Body Surface Area Formulas Are the Same, but Does It Matter?The future of autologous stem cell transplantation in myeloma.The risk of colonic adenomas and colonic cancer in obesityClinical practice guidelines and consensus statements in oncology--an assessment of their methodological quality.Association between baseline body mass index and overall survival among patients over age 60 with acute myeloid leukemiaMorbid obesity as an independent risk factor for disease-specific mortality in women with cervical cancer.Chemotherapy dose adjustment for obese patients undergoing hematopoietic stem cell transplantation: a survey on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.Aggressive estrogen-receptor-positive breast cancer arising in patients with elevated body mass index.Adjuvant chemotherapy dosing in low-income women: the impact of Hispanic ethnicity and patient self-efficacy.Nonalcoholic steatohepatitis in precision medicine: Unraveling the factors that contribute to individual variability.Impact of obesity on chemotherapy management and outcomes in women with gynecologic malignanciesImaging body composition in cancer patients: visceral obesity, sarcopenia and sarcopenic obesity may impact on clinical outcome.The impact of chemotherapy dose intensity and supportive care on the risk of febrile neutropenia in patients with early stage breast cancer: a prospective cohort studyObesity and survival among women with ovarian cancer: results from the Ovarian Cancer Association Consortium.Impact of Chemotherapy Dosing on Ovarian Cancer Survival According to Body Mass Index.The Prognostic Impact of Type 2 Diabetes Mellitus on Early Cervical Cancer in AsiaBody Composition and Anti-Neoplastic Treatment in Adult and Older Subjects - A Systematic Review.
P2860
Q21558465-F73EB6BC-3830-410A-B757-067473CBD7D4Q26775949-3DB2B431-1376-4844-85CF-93E7586748FBQ26786829-866F8793-28F9-4229-9C41-465011B32A6EQ26797301-38DCC497-28CB-4679-985F-CE0E23C570A4Q26822753-85672936-578B-4B51-8973-EA82A598A287Q27014939-B4ABEC08-1CAA-4343-A9A9-4AB072B9CABEQ27340024-36DFAE01-92B3-4083-8507-5B39BB9120D7Q28082947-8DE1EB77-EFB8-4156-96A9-029D8D96ABBAQ28545175-33F5CD77-55B6-4FCE-B8FF-BFFD81F5ADCDQ30249342-3CEED228-6D4F-420E-B6AC-DA45D58699E2Q30313786-CA935BDA-3D4F-4EBC-BE98-186357431E35Q30361298-9851C60F-D2ED-40F2-8A05-CBF02CC149E5Q31154302-BAD52C06-1E40-4243-AD62-D311B8EB259BQ32179246-81B66A0F-CDED-458A-BB6D-6EDAB0877AF9Q33406415-41989515-D808-4337-B7D3-556BD17ED362Q33418378-19527C32-A7EE-47F3-A07B-26C2D97467A7Q33434316-63431099-7198-434A-9873-DA6FFB721EA1Q33618485-D2BE5333-F80D-4DAF-BFB8-73C1FA562AF5Q33697246-A1531A83-62C3-4667-BBFE-7132F78FFC31Q33712501-61BAD469-8D2F-4FB0-A3F4-E4BF43EC96EEQ33714092-01E277FF-6842-410D-ABC6-9ABCCF97298EQ33841425-FC70BFA0-19B6-498B-83BC-3C028FF8335DQ33855312-FAACAB5A-134C-4D92-9BA2-83339448BF04Q33859684-A23D3BC1-7EFD-44CC-BFBC-A92FC0418BD3Q33917164-4C24E40A-7E96-4859-B24E-572F233E53C1Q34157499-D650A4EE-9EF5-4039-B442-F3ABD5C55E4AQ34362184-92198383-1B82-41E4-8FE8-9FCE8192F5AFQ34428550-A90682B6-5C73-4148-9496-51E0F8B7E704Q34598865-95AC1733-C2AA-4F34-99D0-D1E3C1B489DDQ34959952-EDC5C1BE-2CEA-4C42-852A-128D2648A04FQ35186057-28A8D09A-D56B-419D-A07F-AC8DF2C9E754Q35492458-5C969C4E-3058-4DA0-9835-4B8A8ABD1374Q35689076-272B186C-6B61-4D20-82B4-4B5EF60F8BA5Q35748477-A7730BE3-8AF3-4EC7-9158-00DD27D22FFFQ35902270-5E95F3D6-429B-4068-A36B-16DF0B229103Q35916166-B4E116F6-C116-4A93-AA04-75C7A61E4D52Q36027025-29DADFB0-74EF-475D-93DB-6E4516395689Q36053032-CC07EC11-8014-4997-A6AE-D635991DDAC6Q36064889-F793051C-C839-4008-9D93-1B6C15B191BFQ36154581-1D49F832-98A4-4045-A204-89C1D4AAC171
P2860
Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline.
description
2012 nî lūn-bûn
@nan
2012 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Appropriate chemotherapy dosin ...... y clinical practice guideline.
@ast
Appropriate chemotherapy dosin ...... y clinical practice guideline.
@en
Appropriate chemotherapy dosin ...... y clinical practice guideline.
@nl
type
label
Appropriate chemotherapy dosin ...... y clinical practice guideline.
@ast
Appropriate chemotherapy dosin ...... y clinical practice guideline.
@en
Appropriate chemotherapy dosin ...... y clinical practice guideline.
@nl
prefLabel
Appropriate chemotherapy dosin ...... y clinical practice guideline.
@ast
Appropriate chemotherapy dosin ...... y clinical practice guideline.
@en
Appropriate chemotherapy dosin ...... y clinical practice guideline.
@nl
P2093
P356
P1476
Appropriate chemotherapy dosin ...... y clinical practice guideline.
@en
P2093
Carolyn D Runowicz
Edward P Balaban
Gary H Lyman
Gary L Rosner
Holly Anderson
James J Dignam
Jennifer J Griggs
Lara E Sucheston
Michelle Shayne
Pamela B Mangu
P304
P356
10.1200/JCO.2011.39.9436
P407
P577
2012-04-02T00:00:00Z